Efficacy and Safety of Suprachoroidal Triamcinolone Acetonide in Mixed Etiology Non-Infectious Cystoid Macular Edema.

IF 2.1 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-09-15 DOI:10.1097/IAE.0000000000004688

Marcus Yamamoto, Justin Hanson, Alejandro Itzam Marin, Bradley Gundlach, Adrian Au, Kirk Hou, Hamid Hosseini, Moritz Pettenkofer, Colin McCannel, Pradeep Prasad, Judy Chen, Edmund Tsui, Irena Tsui

{"title":"Efficacy and Safety of Suprachoroidal Triamcinolone Acetonide in Mixed Etiology Non-Infectious Cystoid Macular Edema.","authors":"Marcus Yamamoto, Justin Hanson, Alejandro Itzam Marin, Bradley Gundlach, Adrian Au, Kirk Hou, Hamid Hosseini, Moritz Pettenkofer, Colin McCannel, Pradeep Prasad, Judy Chen, Edmund Tsui, Irena Tsui","doi":"10.1097/IAE.0000000000004688","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the efficacy and safety of suprachoroidal triamcinolone acetonide (SCS-TA) in the management of non-infectious cystoid macular edema (CME) of various etiologies.Methods: Retrospective observational study of 61 eyes of 56 patients with non-infectious CME who received SCS-TA injection. Primary outcomes were treatment response, central subfield thickness (CST), visual acuity (VA) and intraocular pressure (IOP) at baseline, one-month, and three months post-injection.Results: CME etiology included post-operative, uveitis, diabetes mellitus, and retinal vein occlusion. Complete resolution of CME occurred in 34 eyes (58.6%) at 1 month and 23 eyes (50.0%) at 3 months. Median CST improved from 430.0 µm (IQR, 366.0-547.5) to 297.0 µm (IQR, 277.0-392.0) at 1 month (p<0.001) and 326.5 µm (IQR, 263.9-380.6) at 3 months (p<0.001). VA improved from logMAR 0.60 (IQR, 0.40-0.88) [20/80] at baseline to 0.48 (IQR, 0.30-0.70) [20/60] at 1 month (p=0.002) and logMAR 0.44 (IQR, 0.18-0.88) [20/60] at 3 months (p=0.019). Significant IOP elevation was noted in 7 eyes (11.5%) overall, with no occurrences of infection, cataract progression, or suprachoroidal hemorrhage.Conclusion: SCS-TA demonstrated significant anatomical and functional improvements in eyes with non-infectious CME and a reassuring side effect profile.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004688","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the efficacy and safety of suprachoroidal triamcinolone acetonide (SCS-TA) in the management of non-infectious cystoid macular edema (CME) of various etiologies.

Methods: Retrospective observational study of 61 eyes of 56 patients with non-infectious CME who received SCS-TA injection. Primary outcomes were treatment response, central subfield thickness (CST), visual acuity (VA) and intraocular pressure (IOP) at baseline, one-month, and three months post-injection.

Results: CME etiology included post-operative, uveitis, diabetes mellitus, and retinal vein occlusion. Complete resolution of CME occurred in 34 eyes (58.6%) at 1 month and 23 eyes (50.0%) at 3 months. Median CST improved from 430.0 µm (IQR, 366.0-547.5) to 297.0 µm (IQR, 277.0-392.0) at 1 month (p<0.001) and 326.5 µm (IQR, 263.9-380.6) at 3 months (p<0.001). VA improved from logMAR 0.60 (IQR, 0.40-0.88) [20/80] at baseline to 0.48 (IQR, 0.30-0.70) [20/60] at 1 month (p=0.002) and logMAR 0.44 (IQR, 0.18-0.88) [20/60] at 3 months (p=0.019). Significant IOP elevation was noted in 7 eyes (11.5%) overall, with no occurrences of infection, cataract progression, or suprachoroidal hemorrhage.

Conclusion: SCS-TA demonstrated significant anatomical and functional improvements in eyes with non-infectious CME and a reassuring side effect profile.

查看原文本刊更多论文

脉络膜上曲安奈德治疗混合病因性非感染性囊样黄斑水肿的疗效和安全性。

目的：评价脉络膜上曲安奈德（SCS-TA）治疗各种病因的非感染性囊样黄斑水肿（CME）的疗效和安全性。方法：对56例接受SCS-TA注射的非感染性CME患者61眼进行回顾性观察。主要结果是治疗反应、注射后1个月和3个月的基线、中心亚野厚度（CST）、视力（VA）和眼压（IOP）。结果：CME病因包括术后、葡萄膜炎、糖尿病和视网膜静脉阻塞。CME在1个月时完全消退34眼（58.6%），在3个月时完全消退23眼（50.0%）。1个月时，中位CST从430.0µm （IQR, 366.0-547.5）改善到297.0µm （IQR, 277.0-392.0）。结论：SCS-TA显示非感染性CME患者的眼睛解剖和功能有显著改善，副作用也令人放心。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.